Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis.
Affiliation
Cancer Research UK, Department of Medical Oncology, Christie Hospital, Withington, Manchester, UK.Issue Date
2005-10
Metadata
Show full item recordAbstract
sanofi-aventis (formerly Aventis) and Regeneron are developing systemic VEGF Trap, a soluble decoy receptor comprising portions of VEGF receptors 1 and 2, for the potential intravenous/subcutaneous treatment of cancer.Citation
Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis. 2005, 7 (5):493-501 Curr. Opin. Mol. Ther.Journal
Current Opinion in Molecular TherapeuticsPubMed ID
16248285Type
ArticleLanguage
enISSN
1464-8431Collections
Related articles
- Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
- Authors: Starzec A, Vassy R, Martin A, Lecouvey M, Di Benedetto M, Crépin M, Perret GY
- Issue date: 2006 Nov 17
- The function of vascular endothelial growth factor.
- Authors: Nieves BJ, D'Amore PA, Bryan BA
- Issue date: 2009 Jul-Aug
- Antitumor activities of synthetic and natural stilbenes through antiangiogenic action.
- Authors: Kimura Y, Sumiyoshi M, Baba K
- Issue date: 2008 Oct
- Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
- Authors: Tortora G, Ciardiello F, Gasparini G
- Issue date: 2008 Sep
- Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling.
- Authors: Awasthi N, Schwarz MA, Verma V, Cappiello C, Schwarz RE
- Issue date: 2009 Jan